IRCT20120520009801N9
Recruiting
Phase 2
Evaluation of the effect of empagliflozin on prevention of atrial fibrillation after coronary artery bypass grafting (CABG) or heart valve replacement: a triple-blind, randomized, placebo-controlled trial
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Atrial fibrillation after heart surgery.
- Sponsor
- Mashhad University of Medical Sciences
- Enrollment
- 160
- Status
- Recruiting
- Last Updated
- 3 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Candidates for heart surgery including CABG or valve replacement
- •70 yr \> age \> 18 yr
- •Taking ACEIs/ARBs, beta\-blockers, statins and aspirin for CABG patients
Exclusion Criteria
- •History of taking empagliflozin drug before surgery
- •Severe heart failure (NYHA Class IV)
- •Renal failure (30 \= GFR)
- •Hepatic failure (hepatic enzymes \> 3 times of upper normal limit )
- •Have pacemaker
- •Have AF rhythm
- •History of heart surgery
- •Very thin people (BMI \= 18\.5 kg/m2\)
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 3
Evaluating the effects of empagliflozin in preventing myocardial damage in patients undergoing percutaneous coronary interventioCardiovascular disease.Cardiovascular disease, unspecified429.2IRCT20221102056378N1Tabriz University of Medical Sciences90
Not Yet Recruiting
Phase 3
Evaluation of the effect of Empagliflozin on the severity of heart failure symptoms and echocardiography parameters in patients with congenital heart diseases with left-to-right shuntIRCT20120520009801N11Mashhad University of Medical Sciences44
Completed
Phase 1
Empagliflozin in non alcoholic fatty liverDiabetic patient with non alcoholic fatty liver.Other specified inflammatory liver diseasesK75.8IRCT20150706023084N18Islamic Azad University30
Completed
Phase 3
Effect of Empagliflozin in prevention of kidney stone parametersIRCT20211203053261N2Hamedan University of Medical Sciences138
Not Yet Recruiting
Phase 3
Effect of Empagliflozin as adjunctive therapy on serum level of oxidative stress biomarkersIRCT20120215009014N486Hamedan University of Medical Sciences80